Fresenius Medical Care AG & Co. (FMS)
(Delayed Data from NYSE)
$25.13 USD
-0.21 (-0.83%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $25.12 -0.01 (-0.04%) 7:58 PM ET
1-Strong Buy of 5 1
B Value C Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FMS 25.13 -0.21(-0.83%)
Will FMS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FMS
Teladoc Health Q2 Loss Narrower Than Expected on Declining Expenses
Here's Why Fresenius (FMS) Looks Ripe for Bottom Fishing
FMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
UnitedHealth Q2 Earnings Miss Estimates on Increasing Medical Costs
Universal Health Q2 Earnings Beat on Strong Acute Care Admissions
Here's Why Fresenius (FMS) is a Strong Value Stock
Other News for FMS
Fresenius Medical Care's Third-Party Clinical Research Organization Frenova Announces Strategic ...
Fresenius Medical Care: Is Trading Below Its Intrinsic Value (Buy)
Oakmark Global Concentrated Strategy Q2 2025 Commentary
Deutsche Bank Adjusts Price Target for Fresenius Medical (FMS) | FMS Stock News
Fresenius Medical price target raised by EUR 5 at Deutsche Bank